Onco-Innovations Scales Up Drug Compound as Stock Volatility Persists

Onco-Innovations advances ONC010 production scale-up but faces stock volatility, no clinical trials, and a 17% YTD loss as investors await clinical data.

The gap between laboratory breakthroughs and market reality remains wide for Onco-Innovations, a biotech firm whose lead drug candidate has yet to enter clinical trials even as its shares have swung wildly in recent weeks.

On April 28, 2026, the company announced it had successfully scaled up production of two key intermediates — A83 and B4 — for its nanoparticle-based PNKP inhibitor ONC010. Working with contract manufacturer Dalton Pharma Services, Onco-Innovations moved the compounds from lab-scale to intermediate-scale batches of roughly 20 and 181 grams, each achieving purity of at least 98 percent as measured by HPLC analysis.

The milestone represents progress in the company's CMC program, the chemical manufacturing and controls framework that underpins regulatory filings. Alongside the scale-up, Onco-Innovations developed an RP-HPLC method for impurity detection and quality control — a building block intended to support future Good Manufacturing Practice (GMP) production.

CEO Thomas O'Shaughnessy framed the achievement as a risk-reduction measure, arguing that establishing a stable supply chain early helps avoid bottlenecks that could delay clinical studies. "This is an important step in de-risking our manufacturing strategy," he said.

Yet the current scale-up does not reach GMP standards, and the company has not disclosed specific volume, yield, or cost figures. Further process optimization is required before clinical-grade material can be produced.

Onco-Innovations is targeting a Phase I trial for colorectal cancer in Australia in 2026, with support from partners Nucro-Technics for preclinical work and Avance Clinical for clinical development planning. The company also plans to list on a U.S. exchange to broaden investor access. In mid-April, it strengthened its leadership team by appointing Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development.

The stock tells a more complicated story. Shares currently trade at €0.75 — roughly 50 percent below the 52-week high of €1.49 but well above the March trough of €0.35. The price sits nearly 10 percent below its 200-day moving average, underscoring how much ground remains to be recovered despite a recent rally.

Over the past 30 days, the stock has nearly doubled, reflecting annualized volatility above 130 percent. But the day-to-day picture is less forgiving: the share price dipped about five percent from the prior session, and year-to-date losses stand at roughly 17 percent.

For now, ONC010 remains a pure development-stage asset with no revenue. The company has not specified when it will file an Investigational New Drug application — the prerequisite for first-in-human testing in the United States. Until that milestone arrives, each incremental step in the lab will be scrutinized, but none can substitute for the clinical data that investors ultimately demand.